Biocon share price today

Biocon Ltd's share price was ₹344.45 at the close on 4 November 2026. It has been falling for 3 weeks. That is 11.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹324 and ₹437, and at that close it sat 18% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Biocon Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 15 weeks running.

Over the last 11 years the share price moved +326% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 24 July 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: profit grew again in the June 2026 quarter, revenue up on a year earlier for 6 quarters in a row and foreign funds (FIIs) raised their stake for 3 quarters in a row.

1. Profit grew again in the June 2026 quarter

   Profit was ₹137 crore, +53.9% on a year earlier (₹89 crore), after 2 quarters of decline.

   Why: Profit rose because the biosimilar business made more money from recent launches and better market access.

   From the earnings call on 6 Aug 2026.

2. Revenue up on a year earlier for 6 quarters in a row

   In the June 2026 quarter revenue was ₹4,336 crore, +10% on a year earlier.

   Why: Revenue rose because biosimilar sales grew.

   Next results: check whether Syngene sales improve in the second half as management expects.

   From the earnings call on 6 Aug 2026.

3. Foreign funds (FIIs) raised their stake for 3 quarters in a row

   From 7.1% to 8.6% of the company by the September 2026 quarter.

For April to June 2026 (the quarter ended 30 June 2026), Biocon reported revenue of ₹4,336 crore, up 10.0% from ₹3,942 crore a year earlier, and a profit of ₹137 crore, up 53.9% from ₹89.0 crore.

Biocon results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Biocon's management discussed these results on a call held on 6 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Biocon closed at ₹344.45 on 4 November 2026, down 9.5% from ₹380.40 a year earlier (7 November 2025) and down 1.2% over five years. Its highest weekly close since March 2016 was ₹481.95 on 24 December 2020.

Biocon share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Biocon closed at ₹344.45, down 2.1% on the week and down 7.1% on the month. 6 Aug 2026: Biocon held its results call for April to June 2026. Management guided: Biosimilars momentum to build progressively through FY27, with meaningful acceleration in H2.

Earlier

• 3 Jul 2026: ex-date for a dividend of ₹0.50 a share.
• Results for April to June 2026: Revenue up 10.0% and profit up 53.9% on a year earlier.

Biocon paid ₹0.50 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.15% at the ₹344.45 close on 4 November 2026. The last was a dividend of ₹0.50 a share, ex-date 3 July 2026.

Biocon dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Biocon Ltd paid out 21% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 6 August 2026, Biocon's management guided: Biosimilars momentum to build progressively through FY27, with meaningful acceleration in H2.

“FY27, we have clearly indicated, is a transition year for Syngene as it navigates the impact of reduced demand from the large biologics client. While revenues are expected to decline in the first half, performance should improve in the second half, resulting in single-digit revenue degrowth in rupee terms for the full year and EBITDA margins returning to the mid-20s.”Kiran Mazdar-Shaw, on the call for April to June 2026

What management guided

• Aflibercept expected to have a good start and build toward H2 as market-access contracts are finalized.
• Malaysia insulin second drug-product line supplies to pick up further from July to September 2026.
• Generics new launches to scale in subsequent quarters, with profitability expanding through utilization and cost programs.
• Biosimilar operating margin to remain in the mid-20s and ramp up through FY27.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 6 August 2026.

When Biocon reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Biosimilar H2 acceleration and payer-contracted growth - check Aflibercept, Denosumab, Aspart, Ustekinumab, and Bevacizumab contribution.

Biocon is on 2 of our India lists: Small & mid cap stocks and Pharma stocks.

Biocon Ltd earned ₹137 Cr of net profit in the Jun 2026 quarter, +53.9% on the same quarter a year earlier. Full-year FY26 profit was ₹369 Cr. Over 10 years profit has grown −4.9% a year on average. That is 3.2% of the quarter's revenue. The same quarter a year earlier earned ₹89.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

1 of the last 12 reported quarters were loss-making.

For the full year, FY26 profit was ₹369 Cr (−74.2% on the year before).

Why profit moved: revenue changed +10.0% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +56.4% and revenue +10.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Biocon Ltd reported ₹4,336 Cr of revenue in the Jun 2026 quarter, +10.0% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 10 years it has grown 17.6% a year on average. The last full year, FY26, came in at ₹16,927 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹17,322 Cr.

FY26 revenue was ₹16,927 Cr, +10.9% on the year before.

Recent pace: the last four quarters grew +10.3% on average, against 17.6% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +9.8%, against +8.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −36.4%, against −54.5% a year (accelerating).

Biocon Ltd's operating margin was 20.0% in the Jun 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 12.0% and 25.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +0.1 percentage points on the year while gross margin changed +1.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 291% of Biocon Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,994 Cr of operating cash against ₹369 Cr of profit. After ₹4,959 Cr of spending on assets, free cash was −₹2,965 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 291% of profit came in as cash: the cash cycle got 49 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 2.3× depreciation over three years. The next section checks what that spending is building.

Biocon Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 85 days in FY26, down from 134 days in FY21. It spent ₹11,901 Cr on assets over the last 3 years. Customers take 129 days to pay, and stock sits for 390 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹16,927 Cr, each day of that cycle ties up about ₹46.4 Cr, so roughly ₹3,942 Cr is tied up in the business at any time.

FY26: customers took 129 days to pay and stock sat for 390 days, about 12.8 months of sales sitting as stock, for a full cycle of 85 days, shorter than FY21's 134.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 390 days. Customers pay about 129 days after that. Suppliers are paid at 434 days. Together that makes the 85-day cycle.

Spending on assets: ₹11,901 Cr over the last 3 years, against ₹5,213 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹6,987 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Biocon Ltd's P/E is 77.1×, near the high end of its own history: higher than 77% of past readings. Its usual P/E (the middle reading) is 51.5×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹3.36.